News archive

Filter by: Reset

June 2021

- June 29, 2021
- KBI Biopharma
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispeci...

Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting canc...
- June 17, 2021
- KBI Biopharma
KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch of Lead P...

Agreement supports future commercial manufacturing for AM-Pharma’s recombinant alkaline phosphatase program
- June 17, 2021
- KBI Biopharma
KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch of Lead P...

Agreement supports future commercial manufacturing for AM-Pharma’s recombinant alkaline phosphatase program
- June 3, 2021
- Crown Bioscience
Crown Bioscience Announces Expedited Access to Well-Established ATCC and NIH Cell Lines for Large-Scale Screening Panels

Five-year licensing agreements strengthen and broaden cell line partnerships

- May 5, 2021
- Crown Bioscience
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings

Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
- May 4, 2021
- KBI Biopharma
Durham Tech and KBI BioPharma Partner to Boost Diversity and Create Life Sciences Job Opportunities for North Carolin...

KBI Biopharma to Offer Manufacturing Apprenticeships as Part of the North Carolina Community College System Apprenticeship NC Program

- March 23, 2021
- JSR Life Sciences
JSR Life Sciences Launches Corporate Venture Fund to Foster Investment in New Companies and Innovative Technologies

Company Appoints Seasoned Life Science Investment and Business Development Executive Dr. Jason Yuanxin Zhang to Lead the Fund
- March 23, 2021
- KBI Biopharma
Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service Agreements
- March 18, 2021
- KBI Biopharma
SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vac...

Selexis SA and SpyBiotech have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV)
- March 16, 2021
- JSR Corporation
JSR Life Sciences Completes Integration of MBL into its Family of Companies

JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...
- March 16, 2021
- KBI Biopharma
Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases

9 of 23